Trial Profile

A Study to Assess the Effect of Single Doses of MK-5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 5475 (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions; Pharmacodynamics
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

29 Nov 2022 Results published in the Respiratory Medicine
03 Jan 2021 Status changed from active, no longer recruiting to completed.
02 Nov 2020 Planned End Date changed from 5 Feb 2021 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com